A biopharmaceutical company focusing on the discovery, development, and commercialization of RNAi therapeutics for treating rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases.
7
Funding Rounds
$886.1m
Money raised
Name | Phone | Social networks | |
---|---|---|---|
Ph***** Sh*** | - | - | - |
Ro**** La**** | - | - | - |
Pa** Sc****** | - | - | - |
Ph***** D. Za**** | - | - | - |
Jo** Cl**** | - | - | - |
Th**** Tu**** | - | - | - |
Da*** Ba**** | - | - | - |
Name | Phone | Social networks | |
---|---|---|---|
Mi***** W. Bo**** | - | - | - |
De**** A. Au****** | - | - | - |
Da*** E.** Py*** | - | - | - |
Am* W. Sc****** | - | - | - |
Ma**** H. Fa***** | - | - | - |
Ol***** Br********* | - | - | - |
YV**** GR********* | - | - | |
Ma****** A. Ha***** | - | - | - |
The company Alnylam Pharmaceuticals has raised a total of $886.1m in funding over 7 rounds.